RxDoctor Payments Data

Christopher Calder, MD

Neurology · Albuquerque, NMNPI 1386693596

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.

$3,263in general payments, 2019–2025

Across 134 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$530
  • Novartis$345
  • UCB, Inc.$285
  • CSL Behring$239
  • AstraZeneca$191
  • Sanofi$138
  • plus $2K from 28 others
$1,343in research payments, 2019–2025

Across 1 payment — averaging $1343.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$1K

What the payments were for

  • Food & beverage$3,24699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,263 in reported general payments places this provider in the 70th percentile of 91 neurology providers in New Mexico.

See all neurology providers in New Mexico

Medicare billing

Part B allowed, 2024
$31,689
Medicare patients
113
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levetiracetam18$1,077
Carbidopa-LevodopaCarbidopa/Levodopa30$926
Primidone18$697
Lamotrigine18$379
Pregabalin18$312
Gabapentin24$252
Phenobarbital14$221
Donepezil Hcl13$173
Clonazepam12$135

Paid to pharmacies, not to this prescriber.

Other neurology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →